Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
A new study finds sodium acetate doesn't protect against acute kidney injury (AKI) in patients undergoing robotic partial nephrectomy overall — but there's a silver lining for higher-risk patients. In a 263-patient retrospective analysis, AKI rates were similar between those who received the drug and those who didn't. Researchers say the benefit may be concentrated in moderate- and high-risk patients, calling for prospective trials in those groups.
A retrospective study presented at IKCS: North America 2026 found that intraoperative sodium acetate does not broadly reduce the risk of acute kidney injury (AKI) in patients undergoing robotic-assisted partial nephrectomy. Across 263 patients, AKI occurred in 13.2% of those who received sodium acetate versus 16.6% of those who didn't — a difference that didn't translate into a meaningful protective effect overall.
However, the picture gets more nuanced when patients are stratified by preoperative risk. In moderate-risk patients, AKI occurred in 13% of the sodium acetate group versus 20% in the control group. High-risk patients also showed a trend toward benefit, while low-risk patients saw no advantage. Researchers suggest any protective effect may be concentrated in patients with elevated preoperative risk, and they're calling for prospective studies in risk-enriched cohorts to confirm these signals.
By the Numbers:
Why it matters: Robotic partial nephrectomy is a common procedure for kidney tumors, and AKI is a significant postoperative complication. If sodium acetate can be shown to benefit higher-risk patients in future prospective trials, it could offer a simple, low-cost intervention to protect kidney function in a vulnerable surgical population.